Epigenetic reprogramming of T cells: unlocking new avenues for cancer immunotherapy
Cancer and Metastasis Reviews · 2024-03 · 43 (1) · 175-195
DOI: 10.1007/s10555-024-10167-w ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer and Metastasis Reviews, online erschienen am 18.01.2024. Verfasst von Vipin Singh und 6 weiteren Autor:innen. Beteiligte Einrichtung: Biophysics and Structural Genomics Division, Saha Institute of Nuclear Physics, 1/AF Bidhannagar, Kolkata, 700064, India. Hauptthemen laut MEDLINE: Epigenesis, Genetic, Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 145 Literaturangaben. Gefördert von: Department of Atomic Energy, Government of India, Department of Biotechnology, Ministry of Science and Technology, India, Department of Science and Technology, Government of India.
Abstract (Originalsprache)
T cells, a key component of cancer immunotherapy, undergo a variety of histone modifications and DNA methylation changes since their bone marrow progenitor stages before developing into CD8+ and CD4+ T cells. These T cell types can be categorized into distinct subtypes based on their functionality and properties, such as cytotoxic T cells (Tc), helper T cells (Th), and regulatory T cells (Treg) as subtypes for CD8+ and CD4+ T cells. Among these, the CD4+ CD25+ Tregs potentially contribute to cancer development and progression by lowering T effector (Teff) cell activity under the influence of the tumor microenvironment (TME). This contributes to the development of therapeutic resistance in patients with cancer. Subsequently, these individuals become resistant to monoclonal antibody therapy as well as clinically established immunotherapies. In this review, we delineate the different epigenetic mechanisms in cancer immune response and its involvement in therapeutic resistance. Furthermore, the possibility of epi-immunotherapeutic methods based on histone deacetylase inhibitors and histone methyltransferase inhibitors are under investigation. In this review we highlight EZH2 as the principal driver of cancer cell immunoediting and an immune escape regulator. We have addressed in detail how understanding T cell epigenetic regulation might bring unique inventive strategies to overcome drug resistance and increase the efficacy of cancer immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Biophysics and Structural Genomics Division, Saha Institute of Nuclear Physics, 1/AF Bidhannagar, Kolkata, 700064, India.
- Homi Bhabha National Institute, Mumbai, 400094, India.
- Indian Institute of Science Education and Research, Kolkata, India.
- Structural Biology & Bio-Informatics Division, CSIR-Indian Institute of Chemical Biology, 4 Raja S. C. Mullick Road, Jadavpur, Kolkata, 700032, India.
- Biophysics and Structural Genomics Division, Saha Institute of Nuclear Physics, 1/AF Bidhannagar, Kolkata, 700064, India. chandrima.das@saha.ac.in.
- Homi Bhabha National Institute, Mumbai, 400094, India. chandrima.das@saha.ac.in.
Förderung
- Department of Atomic Energy, Government of India
- Department of Biotechnology, Ministry of Science and Technology, India
- Department of Science and Technology, Government of India
Zitieren
APA
Singh, V., Nandi, S., Ghosh, A., Adhikary, S., Mukherjee, S., Roy, S., & Das, C. (2024). Epigenetic reprogramming of T cells: unlocking new avenues for cancer immunotherapy. Cancer and Metastasis Reviews, 43(1), 175-195. https://doi.org/10.1007/s10555-024-10167-w
Vancouver
Singh V, Nandi S, Ghosh A, Adhikary S, Mukherjee S, Roy S, et al. Epigenetic reprogramming of T cells: unlocking new avenues for cancer immunotherapy. Cancer and Metastasis Reviews. 2024;43(1):175-195. doi:10.1007/s10555-024-10167-w
BibTeX
@article{Singh2024,
author = {Singh, Vipin and Nandi, Sandhik and Ghosh, Aritra and Adhikary, Santanu and Mukherjee, Shravanti and Roy, Siddhartha and Das, Chandrima},
title = {Epigenetic reprogramming of T cells: unlocking new avenues for cancer immunotherapy},
journal = {Cancer and Metastasis Reviews},
year = {2024},
volume = {43},
number = {1},
pages = {175--195},
doi = {10.1007/s10555-024-10167-w}
}
EUVIMED